MedTrace Logo

Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea

NCT04186494 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-12-18

No results posted yet for this study

Summary

This is an explorative, proof-of-concept study exploring the potential therapeutic role of a Liraglutide-based weight loss regimen versus standard CPAP or the combination of both on metabolic parameters, blood pressure, endothelial function, coronary artery calcification, vascular inflammation and apnea/hypopnea index in non-diabetic patients with moderate to severe obstructive sleep apnea

Conditions

  • Sleep Apnea, Obstructive

Interventions

DRUG

Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml

GLP-1 analogue treatment in combination with advice on diet and physical exercise

DEVICE

Continuous positive airway pressure treatment

Gold standard treatment for obstructive sleep apnea

COMBINATION_PRODUCT

Liraglutide and CPAP

Combination of both treatments

Sponsors & Collaborators

  • University College Dublin

    collaborator OTHER

  • Health Research Board, Ireland

    collaborator OTHER

  • St Vincent's University Hospital, Ireland

    lead OTHER

Principal Investigators

  • Silke Ryan, PhD, MD · St Vincent's University Hospital, University College Dublin

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-02
Primary Completion
2021-12-31
Completion
2022-07-31

Countries

  • Ireland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04186494 on ClinicalTrials.gov